949 related articles for article (PubMed ID: 24750853)
1. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
2. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Rognoni C; Ciani O; Sommariva S; Tarricone R
Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
4. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
6. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
[TBL] [Abstract][Full Text] [Related]
8. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
de la Torre MA; Buades-Mateu J; de la Rosa PA; Lué A; Bustamante FJ; Serrano MT; Testillano M; Lorente S; Arenas JI; Gil C; Iñarrairaegui M; Sangro B
Liver Int; 2016 Aug; 36(8):1206-12. PubMed ID: 26910784
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
10. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Cho YY; Lee M; Kim HC; Chung JW; Kim YH; Gwak GY; Bae SH; Kim do Y; Heo J; Kim YJ
PLoS One; 2016; 11(5):e0154986. PubMed ID: 27149067
[TBL] [Abstract][Full Text] [Related]
12. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Lorenzin D; Pravisani R; Leo CA; Bugiantella W; Soardo G; Carnelutti A; Umberto B; Risaliti A
Cancer Biother Radiopharm; 2016 Mar; 31(2):65-9. PubMed ID: 26986817
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
14. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
15. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
[TBL] [Abstract][Full Text] [Related]
16. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
17. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
18. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
19. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
[TBL] [Abstract][Full Text] [Related]
20. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]